You have 9 free searches left this month | to do more

nivolumab

Nivolumab is a drug used to treat Melanoma, Renal Cell Carcinoma, Metastatic Melanoma, and other conditions. Nivolumab is being actively studied in 633 studies and prior, has been studied in 112.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionIvan S Moiseev
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer CenterInna Chen, MD
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDana Farber Cancer InstituteTheodore Sunki Hong
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Recruiting
  • Melanoma Stage III
  • Melanoma
  • Durham, North Carolina
  • +1 more
2022-03-25
Mar 25, 2022
D
Recruiting
  • Melanoma
  • Vidutolimod (CMP-001)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2022-03-25
Mar 25, 2022
I
Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Nivolumab + Nab-paclitaxel
  • Nivolumab
  • Milan, MI, Italy
    Genitourinary Medical Oncology - IRCCS San Raffaele Hospital and
2022-03-28
Mar 28, 2022
B
Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Combination 5-azacytidine and nivolumab
  • +2 more
  • (no location specified)
2022-03-29
Mar 29, 2022
C
Not yet recruiting
  • Gastric Cancer
  • Chemotherapy Effect
  • Nivolumab plus SOX
  • +2 more
  • (no location specified)
2022-01-07
Jan 7, 2022
C
Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Nivolumab
  • Oral Azacitidine
  • Duarte, California
    City of Hope Medical Center
2022-02-28
Feb 28, 2022
Y
Recruiting
  • Recurrent/Metastatic Carcinosarcoma
  • nivolumab
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System
2022-02-03
Feb 3, 2022
N
Active, not recruiting
  • Ann Arbor Stage III Lymphoma
  • +4 more
  • Bethesda, Maryland
  • +2 more
2022-04-05
Apr 5, 2022
D
Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2022-03-16
Mar 16, 2022
S
Active, not recruiting
  • Neuroendocrine Tumors
  • Carcinoid Tumor
  • Baltimore, Maryland
    Johns Hopkins Medical Institution
2021-12-15
Dec 15, 2021
T
Recruiting
  • Breast Cancer
  • Amsterdam, Netherlands
    NKI-AVL
2022-03-31
Mar 31, 2022
D
Active, not recruiting
  • Thyroid Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-02-18
Feb 18, 2022
S
Recruiting
  • Microsatellite Stable (MSS) Colorectal Adenocarcinomas
  • Colorectal Adenocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2022-03-14
Mar 14, 2022
R
Active, not recruiting
  • Renal Cell Carcinoma
  • Washington, District of Columbia
  • +1 more
2022-01-10
Jan 10, 2022
S
Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2022-03-14
Mar 14, 2022
D
Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-07-22
Jul 22, 2021
S
Recruiting
  • Multiple Myeloma
  • Saint Petersburg, Russian Federation
    Boris V Afanasyev, MD, Prof.
2022-04-04
Apr 4, 2022
A
Recruiting
  • Metastatic Melanoma
  • Hypofractionated Radiation Therapy (HFRT)
  • +2 more
  • Lancaster, Pennsylvania
  • +1 more
2022-03-30
Mar 30, 2022
T
Active, not recruiting
  • Breast Cancer
  • Nivolumab
  • +4 more
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
2022-03-21
Mar 21, 2022
I
Recruiting
  • Metastatic Melanoma
  • Nivolumab
  • PD-L1/IDO peptide vaccine
  • Herlev, Denmark
  • +1 more
2022-03-15
Mar 15, 2022
N
Suspended
  • Acute Myeloid Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-04-05
Apr 5, 2022
A
Active, not recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • Nivolumab
  • Amsterdam, Noord-Holland, Netherlands
    VU University medical center
2021-10-06
Oct 6, 2021
S
Recruiting
  • Nasopharyngeal Carcinoma
  • Nivolumab
  • +2 more
  • San Francisco, California
  • +1 more
2022-02-07
Feb 7, 2022